Devonian Health Group (CVE:GSD) Trading Up 0.3% – Here’s What Happened

Devonian Health Group Inc. (CVE:GSD) shares shot up 0.3% during mid-day trading on Wednesday . The company traded as high as C$9.00 and last traded at C$8.01. Approximately 700 shares changed hands during mid-day trading, a decline of 55% from the average daily volume of 1,550 shares. The stock had previously closed at C$7.99.

Devonian Health Group Stock Performance

The company has a 50 day moving average of C$8.84 and a 200 day moving average of C$10.43. The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36. The firm has a market cap of C$22.25 million, a price-to-earnings ratio of -3.56 and a beta of 0.03.

Devonian Health Group Company Profile

Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.